迈威生物：创新药9MW1911已完成在COPD患者中的IIa 期临床研究

Core Viewpoint - Maiwei Biotech (688062.SH) announced the successful completion of Phase IIa clinical trials for its innovative drug 9MW1911 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), demonstrating good safety and tolerability across all dosage groups [1] Group 1: Clinical Research Results - In the recommended dosage for Phase IIb studies, the annual incidence of acute exacerbations in moderate to severe COPD patients was reduced by over 30% compared to the placebo group [1] - The annual incidence of severe acute exacerbations decreased by over 40%, with a significant reduction in the proportion of patients experiencing severe acute exacerbations [1] - The company is actively advancing the Phase IIb clinical research for 9MW1911 in the COPD indication [1]